SAB Biotherapeutics (SABS) Notes Payables (2020 - 2025)

SAB Biotherapeutics (SABS) has 6 years of Notes Payables data on file, last reported at $138554.0 in Q1 2025.

• Quarterly Notes Payables fell 83.42% year-over-year to $138554.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $138554.0 (down 83.42% YoY) and the FY2024 annual result came in at $275849.0, down 73.75% from the prior year.
• Notes Payables declined to $138554.0 in Q1 2025, from $275849.0 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $1.8 million in Q4 2021 to a low of $25013.0 in Q3 2022.
• A 5-year average of $609781.8 and a median of $541644.0 in 2023 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2023 — Notes Payables surged 2065.45% — and 2025, when it slumped 83.42%.
• Tracing SABS's Notes Payables over 5 years: stood at $1.8 million in 2021, then plunged by 57.0% to $772665.0 in 2022, then jumped by 36.0% to $1.1 million in 2023, then plunged by 73.75% to $275849.0 in 2024, then sank by 49.77% to $138554.0 in 2025.
• The last three Notes Payables figures came in at $138554.0 (Q1 2025), $275849.0 (Q4 2024), and $615818.0 (Q2 2024), per Business Quant data.